CO2023008442A2 - Inhibidores de la atp sintasa - usos cosméticos y terapéuticos - Google Patents

Inhibidores de la atp sintasa - usos cosméticos y terapéuticos

Info

Publication number
CO2023008442A2
CO2023008442A2 CONC2023/0008442A CO2023008442A CO2023008442A2 CO 2023008442 A2 CO2023008442 A2 CO 2023008442A2 CO 2023008442 A CO2023008442 A CO 2023008442A CO 2023008442 A2 CO2023008442 A2 CO 2023008442A2
Authority
CO
Colombia
Prior art keywords
teaches
optionally
cosmetic
atp
protein
Prior art date
Application number
CONC2023/0008442A
Other languages
English (en)
Inventor
Michael David Forrest
Original Assignee
Michael David Forrest
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Michael David Forrest filed Critical Michael David Forrest
Publication of CO2023008442A2 publication Critical patent/CO2023008442A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/86—Products or compounds obtained by genetic engineering
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pistons, Piston Rings, And Cylinders (AREA)
  • Retarders (AREA)
  • Cosmetics (AREA)

Abstract

Con datos experimentales de apoyo, esta divulgación enseña que la actividad de la proteína IF1 es un determinante molecular de la vida útil, lo que explica por qué diferentes especies tienen diferentes vidas útiles máximas, y enseña una proteína/fragmento IF1 (o una variante de secuencia de la misma), o una proteína de fusión de la misma, opcionalmente una proteína de fusión que comprende una secuencia de péptido de penetración celular (CPP), como agente para ralentizar/retrasar/reducir el envejecimiento en un sujeto, opcionalmente como componente de un cosmético, opcionalmente para tratar una enfermedad/trastorno relacionado con la edad. Además, enseña otros inhibidores de la hidrólisis de F1F0 ATP, incluidas moléculas pequeñas, de varios andamios diferentes, para este propósito. Además, con datos experimentales de apoyo, enseña quecompuestos que retardanel modo de hidrolización de ATP de la ATP sintasa es útil para tratar diversas enfermedades y trastornos, incluido el cáncer, en particular los cánceres que utilizan el efecto Warburg.
CONC2023/0008442A 2021-01-24 2023-06-27 Inhibidores de la atp sintasa - usos cosméticos y terapéuticos CO2023008442A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2021/050529 WO2022157548A1 (en) 2021-01-24 2021-01-24 Inhibitors of atp synthase - cosmetic and therapeutic uses

Publications (1)

Publication Number Publication Date
CO2023008442A2 true CO2023008442A2 (es) 2023-09-18

Family

ID=74587080

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0008442A CO2023008442A2 (es) 2021-01-24 2023-06-27 Inhibidores de la atp sintasa - usos cosméticos y terapéuticos

Country Status (10)

Country Link
EP (1) EP4281034A1 (es)
KR (1) KR20230135586A (es)
CN (1) CN117157049A (es)
AU (1) AU2021421391A1 (es)
BR (1) BR112023012422A2 (es)
CA (1) CA3206148A1 (es)
CO (1) CO2023008442A2 (es)
IL (1) IL303969A (es)
MX (1) MX2023007788A (es)
WO (1) WO2022157548A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117393044B (zh) * 2023-12-11 2024-02-27 四川大学华西医院 一种用于轻度认知障碍症早期筛查的试剂盒及诊断系统

Family Cites Families (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4542025A (en) 1982-07-29 1985-09-17 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US5573933A (en) 1987-04-14 1996-11-12 Luminis Pty, Ltd. Transgenic pigs
US5532220A (en) 1987-08-31 1996-07-02 The Regents Of The University Of California Genetic mechanisms of tumor suppression
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5240846A (en) 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5747641A (en) 1989-12-21 1998-05-05 Biogen Inc Tat-derived transport polypeptide conjugates
US6316003B1 (en) 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
JPH07500961A (ja) 1990-10-01 1995-02-02 ユニバーシティ オブ コネチカット 細胞による選択的内在化を目的としたウイルス及び細胞の標的設定
US5831141A (en) 1991-01-11 1998-11-03 United States Of America As Represented By The Department Of Health And Human Services Expression of a heterologous polypeptide in mammary tissue of transgenic non-human mammals using a long whey acidic protein promoter
WO1992020316A2 (en) 1991-05-14 1992-11-26 University Of Connecticut Targeted delivery of genes encoding immunogenic proteins
AU2160992A (en) 1991-06-05 1993-01-12 Board Of Regents Acting For And On Behalf Of The University Of Michigan, The Targeted delivery of genes encoding secretory proteins
AU3434393A (en) 1992-01-17 1993-08-03 Regents Of The University Of Michigan, The Targeted virus
US5338843A (en) 1992-01-30 1994-08-16 Becton, Dickinson And Company Fluorogenic and chromogenic β-lactamase substrates
JPH07505773A (ja) 1992-04-03 1995-06-29 ヤング　アレキサンダー　ティー 標的化されたウイルスベクターを用いた遺伝子治療
US5565324A (en) 1992-10-01 1996-10-15 The Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
AU689758B2 (en) 1992-10-09 1998-04-09 Advanced Tissue Sciences, Inc. Liver reserve cells
CA2592997A1 (en) 1992-12-03 1994-06-09 Genzyme Corporation Pseudo-adenovirus vectors
NZ265091A (en) 1993-04-21 1997-07-27 Univ Edinburgh Dna constructs for inserting heterologous gene sequences into a host genome
ATE301201T1 (de) 1993-06-07 2005-08-15 Vical Inc Für die gentherapie verwendbare plasmide
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5942496A (en) 1994-02-18 1999-08-24 The Regent Of The University Of Michigan Methods and compositions for multiple gene transfer into bone cells
US5962427A (en) 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
FR2718329B1 (fr) 1994-03-21 2002-09-20 Rhone Poulenc Rorer Sa Lapin transgénique sensibilisé aux dyslipoprotéinémies.
US5675060A (en) 1994-05-19 1997-10-07 Institut National De La Sante Et De La Recherche Medicale Transgenic arthritic mice expressing a T-cell receptor transgene
US5850001A (en) 1994-06-06 1998-12-15 Universite De Montreal Transgenic mouse for the neuronal expression of HIV gp160
US5907030A (en) 1995-01-25 1999-05-25 University Of Southern California Method and compositions for lipidization of hydrophilic molecules
US5669907A (en) 1995-02-10 1997-09-23 Valleylab Inc. Plasma enhanced bipolar electrosurgical system
US5814300A (en) 1995-03-03 1998-09-29 Cephalon, Inc. Gene-targeted non-human mammals deficient in the SOD-1 gene
US5741657A (en) 1995-03-20 1998-04-21 The Regents Of The University Of California Fluorogenic substrates for β-lactamase and methods of use
US5751629A (en) 1995-04-25 1998-05-12 Irori Remotely programmable matrices with memories
CN1208438A (zh) 1995-07-28 1999-02-17 玛丽·柯里癌症治疗中心 转运蛋白及其应用
FR2739621B1 (fr) 1995-10-05 1997-12-05 Centre Nat Rech Scient Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives
ATE272058T1 (de) 1995-10-17 2004-08-15 Combichem Inc Matrize für die synthese kombinatorischer bibliotheken in lösung
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
AU6990796A (en) 1996-08-23 1998-03-06 Sederma Sa Synthetic peptides and their use in cosmetic or dermopharmaceutical compositions
PL192359B1 (pl) 1996-08-30 2006-10-31 Novo Nordisk As Pochodna GLP-1(7-37) lub analogu GLP-1(7-37), środek farmaceutyczny oraz zastosowanie pochodnej GLP-1(7-37) lub analogu GLP-1(7-37)
US5928888A (en) 1996-09-26 1999-07-27 Aurora Biosciences Corporation Methods and compositions for sensitive and rapid, functional identification of genomic polynucleotides and secondary screening capabilities
US5906923A (en) 1996-10-02 1999-05-25 Incyte Pharmaceuticals, Inc. ATPase inhibitor
US5798035A (en) 1996-10-03 1998-08-25 Pharmacopeia, Inc. High throughput solid phase chemical synthesis utilizing thin cylindrical reaction vessels useable for biological assay
GB9714680D0 (en) 1997-07-11 1997-09-17 Medical Res Council Recombinant production of proteins
US6093692A (en) 1997-09-25 2000-07-25 The University Of Southern California Method and compositions for lipidization of hydrophilic molecules
ATE466027T1 (de) 1998-02-27 2010-05-15 Novo Nordisk As Abkömmlinge von glp-1 analogen
GB9814527D0 (en) 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
FR2783169B1 (fr) 1998-09-15 2001-11-02 Sederma Sa Utilisation cosmetique ou dermopharmaceutique de peptides pour la cicatrisation et pour l'amelioration de l'aspect cutane lors du vieillissement naturel ou accelere (heliodermie, pollution)
US6492326B1 (en) 1999-04-19 2002-12-10 The Procter & Gamble Company Skin care compositions containing combination of skin care actives
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6730293B1 (en) 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20030026781A1 (en) 1999-11-10 2003-02-06 Mitokor Compositions and methods for regulating endogenous inhibitor of ATP synthase, including treatment for diabetes
CA2390646A1 (en) * 1999-11-10 2001-05-17 Mitokor Compositions and methods for regulating endogenous inhibitor of atp synthase, including treatment for diabetes
US20040072739A1 (en) 1999-11-10 2004-04-15 Anderson Christen M. Compositions and methods for regulating endogenous inhibitor of ATP synthase, including treatment for diabetes
SE0002232D0 (sv) 2000-06-15 2000-06-15 Vulpes Ltd Antioxidant
ATE437647T1 (de) 2001-02-16 2009-08-15 Cellgate Inc Transporter mit beabstandeten arginin-teilchen
US7049286B2 (en) 2001-08-30 2006-05-23 Diatos, S.A. Insulin conjugates and methods of use thereof
FR2830195B1 (fr) 2001-10-03 2004-10-22 Sederma Sa Compositions cosmetiques et dermopharmaceutiques pour les peaux a tendance acneique
ATE510852T1 (de) 2001-10-30 2011-06-15 Dsm Ip Assets Bv Dermopharmazeutisch und kosmetisch wirksame oligopeptide
TW200408407A (en) 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
FR2836042B1 (fr) 2002-02-15 2004-04-02 Sederma Sa Compositions cosmetiques ou dermopharmaceutiques pour diminuer les poches et cernes sous les yeux
CA2482598C (en) 2002-04-22 2012-09-25 The Board Of Trustees Of The Leland Stanford Junior University Peptide inhibitors of protein kinase c
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
US7863417B2 (en) 2003-05-08 2011-01-04 Dsm Ip Assets B.V. Tripeptides and derivatives thereof for cosmetic application in order to improve skin structure
US7208595B2 (en) 2003-07-25 2007-04-24 The Ohio State University Research Foundation Peptide deformylase inhibitors as novel antibiotics
US9695251B2 (en) 2003-10-31 2017-07-04 The Regents Of The University Of California Activatable cell penetrating peptides with quenched fluorophores
US7431915B2 (en) 2003-10-31 2008-10-07 The Regents Of The University Of California Peptides whose uptake by cells is controllable
WO2011008992A2 (en) 2009-07-15 2011-01-20 The Regents Of The University Of California Peptides whose uptake in cells is controllable
US7985401B2 (en) 2003-10-31 2011-07-26 The Regents Of The University Of California Peptides whose uptake by cells is controllable
ATE548022T1 (de) 2003-11-17 2012-03-15 Sederma Sa Zusammensetzungen mit einer kombination von tetrapeptiden und tripeptiden
SG150570A1 (en) 2004-03-03 2009-03-30 Revance Therapeutics Inc Compositions and methods for topical diagnostic and therapeutic transport
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US7265092B2 (en) 2004-09-30 2007-09-04 Kai Pharmaceuticals, Inc. Pharmaceutical formulation
CN102499981B (zh) 2005-03-03 2016-08-03 雷文斯治疗公司 用于局部施用和经皮肤递送肉毒杆菌毒素的组合物和方法
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007035474A2 (en) 2005-09-15 2007-03-29 Novomed Technologies, Inc. (Shanghai) Transdermal delivery peptides and method of use thereof
US7659252B2 (en) 2005-09-15 2010-02-09 Novomed Technologies, Inc. (Shanghai) Transdermal delivery peptides and method of use thereof
EP1984387B1 (en) 2006-02-16 2017-05-31 Sederma Polypeptides kxk and their use
EP1991586B1 (en) 2006-03-20 2011-01-12 Cepep III AB Chimeric constructs between cancer-homing peptides and cell-penetrating peptides coupled to anticancer drugs and/or diagnostic agent/agents
JP5313867B2 (ja) 2006-03-30 2013-10-09 ドライス ファーマシューティカルズ，インコーポレイティド カンプトテシン−細胞透過性ペプチド複合体及びそれを含む医薬組成物
CN101583274A (zh) 2006-12-29 2009-11-18 雷文斯治疗公司 使用反向序列hiv-tat多肽的运输分子
JP2010516707A (ja) 2007-01-19 2010-05-20 カイ ファーマシューティカルズ インコーポレーティッド ペプチド組成物の安定性および送達効率を上昇させるための修飾方法
EP2200653A2 (en) 2007-09-10 2010-06-30 University of Massachusetts Mitochondria-targeted anti-tumour agents
EP2653543A1 (en) 2008-02-05 2013-10-23 Bicycle Therapeutics Limited Methods and Compositions
ES2330291B1 (es) 2008-02-29 2010-10-18 Lipotec Sa Peptidos utiles en el tratamiento de la piel, mucosas y/o cuero cabelludo y su uso en composiciones cosmeticas o farmaceuticas.
CN102119217B (zh) 2008-04-15 2015-06-03 普洛体维生物治疗公司 用于核酸递送的新型制剂
JP5635512B2 (ja) 2008-09-16 2014-12-03 カリエム・アーメド 遺伝子調節化合物の改良された送達のための化学的に修飾された細胞透過性ペプチド
US20100311671A1 (en) 2009-03-25 2010-12-09 Kai Pharmaceuticals Transdermal delivery of pkc modulatory peptides through microporated skin
TWI487533B (zh) 2009-07-24 2015-06-11 Lipotec Sa 抑制肌肉收縮的化合物
CA2785834A1 (en) 2010-01-06 2011-07-14 The University Of North Carolina At Chapel Hill Fatty acid derivatives and analogs of drugs
CA2800741C (en) 2010-05-30 2018-07-24 The Governing Council Of The University Of Toronto Mitochondrial penetrating peptides as carriers for anticancer compounds
US20130078295A1 (en) 2010-06-09 2013-03-28 Lipotec S.A. Skin antiaging treatment
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
US9408542B1 (en) 2010-07-22 2016-08-09 Masimo Corporation Non-invasive blood pressure measurement system
HUE058896T2 (hu) 2010-10-01 2022-09-28 Modernatx Inc N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai
CN103201386A (zh) 2010-11-09 2013-07-10 加利福尼亚大学董事会 皮肤穿透及细胞进入(space)肽及其使用方法
JP6091435B2 (ja) 2011-02-22 2017-03-08 カリフォルニア インスティチュート オブ テクノロジー アデノ随伴ウイルス（ａａｖ）ベクターを用いたタンパク質の送達
ES2397890B1 (es) 2011-03-25 2014-02-07 Lipotec, S.A. Péptidos útiles en el tratamiento y/o cuidado de la piel y/o mucosas y su uso en composiciones cosméticas o farmacéuticas.
CA2836299A1 (en) 2011-04-15 2012-10-18 Genelux Corporation Clonal strains of attenuated vaccinia viruses and methods of use thereof
TWI497333B (zh) 2011-06-14 2015-08-21 Giant Mfg Co Ltd 自行車適配產生方法、自行車適配系統與電腦程式產品
WO2013064583A1 (en) 2011-11-04 2013-05-10 Lipotec, S.A. Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
EP3656394A1 (en) 2011-12-09 2020-05-27 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9104666B2 (en) 2012-09-04 2015-08-11 Oracle International Corporation Controlling access to a large number of electronic resources
FR2998570B1 (fr) 2012-11-26 2016-12-02 Sederma Sa Peptides, compositions les comprenant et utilisations notamment cosmetiques propigmentantes
WO2014120837A2 (en) 2013-01-29 2014-08-07 The Regents Of The University Of California Pretargeted activatable cell penetrating peptide with intracellulary releaseable prodrug
WO2014123543A2 (en) 2013-02-11 2014-08-14 Convoy Therapeutics Skin permeating and cell entering (space) peptides and methods of use therefor
US20140227174A1 (en) 2013-02-11 2014-08-14 The Regents Of The University Of California Skin permeating and cell entering (space) peptides and methods of use therefor
US20140234275A1 (en) 2013-02-15 2014-08-21 Jason Williams Method for treating als via the increased production of factor h
US10577303B1 (en) 2013-03-14 2020-03-03 Wisconsin Alumni Research Foundation Reagents and methods for esterification
US10287331B2 (en) 2013-04-15 2019-05-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Mitochondrial proteins constructs and uses thereof
EP2792684A1 (en) 2013-04-15 2014-10-22 Lipotec, S.A. Compounds useful in the treatment and/or care of the skin and their cosmetic or pharmaceutical compositions
US9868767B2 (en) 2013-05-23 2018-01-16 Ohio State Innovation Foundation Chemical synthesis and screening of bicyclic peptide libraries
WO2014210056A1 (en) 2013-06-27 2014-12-31 Stealth Peptides International, Inc. Peptide therapeutics and methods for using same
GB2516045A (en) 2013-07-09 2015-01-14 Neuro Bio Ltd Neurodegenerative disorders
JP6063094B2 (ja) 2013-08-12 2017-01-18 スリーエム イノベイティブ プロパティズ カンパニー 経皮送達を促進するためのペプチド
WO2015179438A1 (en) 2014-05-20 2015-11-26 Ohio State Innovation Foundation Small molecule rac or rho inhibitors
US10815276B2 (en) 2014-05-21 2020-10-27 Entrada Therapeutics, Inc. Cell penetrating peptides and methods of making and using thereof
JP6807831B2 (ja) 2014-05-21 2021-01-06 エントラーダ セラピューティクス，インコーポレイテッド 細胞膜透過性ペプチド、並びにこの作製方法及び使用方法
FR3021319B1 (fr) 2014-05-22 2018-08-31 Sederma Peptides, compositions les comprenant et utilisations notamment cosmetiques
US20170258930A1 (en) 2014-08-27 2017-09-14 The Regents Of The University Of California Skin penetrating peptides (spps) and methods of use therefor
US10258695B2 (en) 2014-09-04 2019-04-16 Wisconsin Alumni Research Foundation Protein derivatization to endow cell penetration
US10385380B2 (en) 2014-10-02 2019-08-20 The Regents Of The University Of California Personalized protease assay to measure protease activity in neoplasms
PT3215518T (pt) 2014-10-29 2021-05-25 Bicyclerd Ltd Ligantes de péptido bicíclicos específicos para mt1-mmp
GB2539161A (en) 2014-11-26 2016-12-14 Neuro-Bio Ltd Neurodegenerative disorders
FR3029782B1 (fr) 2014-12-16 2019-06-07 Sederma Composes peptidiques, compositions les comprenant et utilisations notamment cosmetiques
RU2017128116A (ru) 2015-01-23 2019-02-26 Эразмус Юниверсити Медикал Сентр Роттердам Соединения, препятствующие старению, и способы их применения
US9790483B2 (en) 2015-04-09 2017-10-17 Wisconsin Alumni Research Foundation Reagents and methods for esterification
US10596259B2 (en) 2015-05-20 2020-03-24 The Regents Of The University Of California Tumor radiosensitization with monomethyl auristatin E (MMAE) and derivatives thereof
US20180251495A1 (en) 2015-09-15 2018-09-06 The Regents Of The University Of California Skin-Penetrating Peptides and Compositions and Methods of Use Thereof
SI3350157T1 (sl) 2015-09-17 2022-04-29 Modernatx, Inc. Sestave za doziranje terapevtskih sredstev v celice
MD3718565T2 (ro) 2015-10-22 2022-09-30 Modernatx Inc Vaccinuri împotriva virusului respirator
GB201607827D0 (en) 2016-05-04 2016-06-15 Bicycle Therapeutics Ltd Bicyclic peptide-toxin conjugates specific for MT1-MMP
US11351222B2 (en) 2016-11-09 2022-06-07 Ohio State Innovation Foundation Di-sulfide containing cell penetrating peptides and methods of making and using thereof
US20190309020A1 (en) 2016-11-22 2019-10-10 Ohio State Innovation Foundation Cell-penetrating peptide sequences
WO2018098282A2 (en) 2016-11-22 2018-05-31 Ohio State Innovation Foundation Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof
WO2018098226A1 (en) 2016-11-22 2018-05-31 Ohio State Innovation Foundation Bicyclic peptidyl inhibitor of tumor necrosis factor-alpha
EP3565638B8 (en) 2017-01-06 2024-04-10 BicycleRD Limited Bicycle conjugate for treating cancer
WO2018232491A1 (en) 2017-06-23 2018-12-27 The Governing Council Of The University Of Toronto MITOCHONDRIAL TARGETING RELEASABLE
SG11202000331YA (en) 2017-07-13 2020-02-27 Michael David Forrest Therapeutic modulators of the reverse mode of atp synthase
US11339192B2 (en) 2017-10-04 2022-05-24 Ohio State Innovation Foundation Bicyclic peptidyl inhibitors
WO2019148194A2 (en) 2018-01-29 2019-08-01 Ohio State Innovation Foundation Peptidyl inhibitors of calcineurin-nfat interaction
WO2019148195A2 (en) 2018-01-29 2019-08-01 Ohio State Innovation Foundation Cyclic peptidyl inhibitors of cal-pdz binding domain
FR3077202B1 (fr) 2018-02-01 2020-01-10 Sederma Utilisation de cyclopeptides en cosmetique
WO2019199841A1 (en) 2018-04-09 2019-10-17 Cure Ahc, Inc. Aav-mediated delivery of atp1a3 genes to central nervous system
CA3050553A1 (en) 2019-07-25 2021-01-25 Michael D. Forrest Therapeutic modifiers of the reverse mode of atp synthase

Also Published As

Publication number Publication date
CA3206148A1 (en) 2022-07-28
AU2021421391A1 (en) 2023-07-20
CN117157049A (zh) 2023-12-01
EP4281034A1 (en) 2023-11-29
BR112023012422A2 (pt) 2023-12-12
WO2022157548A1 (en) 2022-07-28
MX2023007788A (es) 2023-11-17
KR20230135586A (ko) 2023-09-25
IL303969A (en) 2023-08-01

Similar Documents

Publication Publication Date Title
CO2023008442A2 (es) Inhibidores de la atp sintasa - usos cosméticos y terapéuticos
ATE524546T1 (de) Verwendung von anti-tnf oder anti-il1-rnai zur unterdrückung der wirkung entzündungsfördernder cytokine zur lokalen schmerzbehandlung
EA201691079A1 (ru) Комбинированная терапия для лечения онкологического заболевания
GT201700246A (es) Métodos y kits para tratar la depresión
CU23880B1 (es) Anticuerpos monoclonales contra el inhibidor de la vía del factor tisular (tfpi)
MX2021007570A (es) Composiciones de agente de arni de la proteina precursora del amiloide (app) y metodos de uso de las mismas.
EA201890009A1 (ru) Ингибиторы ezh2 для лечения лимфомы
CY1114153T1 (el) Παραγωγα κυκλοαλκανοπυρρολοκαρβαzολιου και η χρηση αυτων ως αναστολεις parp, vegfr2 και mlk3
BR112016004095A2 (pt) administração de enzimas de empobrecimento de quinurenina para a terapia contra tumores
EA201001204A1 (ru) Методы и композиции, в которых применяют слитые полипептиды klotho-fgf
GT201700224A (es) Proteína de unión a rgma y su uso
BR112019000215A2 (pt) depleção de cistina mediada por enzima humana
BRPI0919020B8 (pt) uso de células de linhagem monocitária enriquecidas para tratar isquemia e para tratar angina pectoris
GT201200275A (es) Proteína de fusión robo1-fc y su utilización en el tratamiento de tumores
BR112014009785A8 (pt) método para tratar ou reduzir efp
DE602006011607D1 (de) In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie
WO2012178156A3 (en) Laser assisted delivery of functional cells, peptides and nucleotides
BRPI0713731B8 (pt) agente indutor de imunidade direcionado contra cânceres, medicamento para tratar e/ou prevenir tumores, e, agente para induzir células
BRPI0512503A (pt) composição que compreende ácido lático e lactoferrina
BR112018072339A2 (pt) tratamento de distúrbios de perda de cabelo com inibidores de jak deuterados
AR110031A1 (es) Métodos de tratamiento de pacientes con cáncer con inhibidores de farnesiltransferasa
BR112015021483A2 (pt) arginina deiminase com reduzida reatividade cruzada para anticorpos adi-peg 20 para o tratamento do câncer
BR112014024358A8 (pt) administração subcutânea de iduronato-2-sulfatase
EA202193111A1 (ru) Композиции и способы для лечения рака
JP2023098960A (ja) 老化細胞および細胞老化関連分泌形質による発毛の刺激